Notoginsenoside R1

SKU: orb1304798

Description

Notoginsenoside R1, a primary saponin monomer from Panax ginseng, exhibits diverse bioactivities including cardiovascular and neuroprotective effects. It is widely used in research for in vitro and in vivo studies exploring its mechanisms in oncology, immunology, and hepatoprotection.

Research Area

Cell Biology, Neuroscience, Signal Transduction

Key Properties

• CAS Number: 80418-24-2
• MW: 933.13
• Purity: >99.99% (May vary between batches)
• Formula: C₄₇H₈₀O₁₈
• SMILES: [H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@]1([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@]1([H])OC[C@@H](O)[C@H](O)[C@H]1O)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
• Target: Apoptosis,Beta Amyloid,ERK
• Solubility: 10% DMSO+90% Saline:2.5 mg/mL (2.68 mM);H2O:2.5 mg/mL (2.68 mM);DMSO:247.5 mg/mL (265.24 mM)

Bioactivity

• In Vivo:
  METHODS: To study the effect on neoplastic endothelial hyperplasia, Notoginsenoside R1 (10 mg/kg) was administered intraperitoneally to C57BL/6 J mice once daily for three weeks. A mouse femoral artery injury model was subsequently performed. RESULTS: Notoginsenoside R1 attenuated neointimal formation after femoral artery injury in vivo.Notoginsenoside R1 treatment reduced neointimal formation by inhibiting VSMC proliferation.
• In Vitro:
  METHODS: Human colorectal cancer cells HCT-116 were treated with Notoginsenoside R1 (75-300 µM) for 48 h. Cell viability was measured by MTT assay. RESULTS: Cell viability of HCT-116 cells treated with 75-300 µM Notoginsenoside R1 was not significantly different from that of the control. However, treatment with 500 µM Notoginsenoside R1 for 48 h resulted in a significant decrease in cell viability (58±7.26%) compared to control cells. METHODS: Human coronary artery smooth muscle cells hCASMC were treated with Notoginsenoside R1 (10 µM) for 24 h. The cells were stimulated with 10% FBS for 0-30 min, and the expression levels of target proteins were detected by Western Blot. RESULTS: Akt phosphorylation in hCASMCs was rapidly reduced in a time- and dose-dependent manner after Notoginsenoside R1 treatment, but no effect on ERK1/2 and JNK signaling was observed. notoginsenoside R1 caused a modest reduction in p38 MAPK phosphorylation, but this did not reach significance.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BetaAmyloid, Beta Amyloid, Abeta, Amyloid-β, Apoptosis, anti-oxidation, anti-inflammatory, anti-apoptosis,cardioprotection, anti-angiogenic, bAmyloid, b Amyloid, I/R, ERK1, ERK2, Notoginsenoside R 1, Notoginsenoside R1, Notoginsenoside R-1, Inhibitor, inhibit, neuroprotection, Sanchinoside R 1, Sanchinoside R1, Sanchinoside R-1, Sanqi glucoside R 1, Sanqi glucoside R1, Sanqi glucoside R-1, saponin, βAmyloid, β-amyloid peptide, β Amyloid

Compound Identifiers

PubChem CID

441934